- Home
- AZTA vs DVAX Comparison
AZTA vs DVAX Comparison
Compare AZTA & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AZTA
- DVAX
- Stock Information
- Founded
- AZTA 1978
- DVAX 1996
- Country
- AZTA United States
- DVAX United States
- Employees
- AZTA N/A
- DVAX N/A
- Industry
- AZTA Industrial Machinery/Components
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- AZTA Technology
- DVAX Health Care
- Exchange
- AZTA Nasdaq
- DVAX Nasdaq
- Market Cap
- AZTA 1.4B
- DVAX 1.3B
- IPO Year
- AZTA 1995
- DVAX 2004
- Fundamental
- Price
- AZTA $34.43
- DVAX $11.36
- Analyst Decision
- AZTA Buy
- DVAX Buy
- Analyst Count
- AZTA 3
- DVAX 4
- Target Price
- AZTA $45.00
- DVAX $26.25
- AVG Volume (30 Days)
- AZTA 954.7K
- DVAX 1.6M
- Earning Date
- AZTA 08-05-2025
- DVAX 08-05-2025
- Dividend Yield
- AZTA N/A
- DVAX N/A
- EPS Growth
- AZTA N/A
- DVAX N/A
- EPS
- AZTA N/A
- DVAX N/A
- Revenue
- AZTA $669,171,000.00
- DVAX $294,620,000.00
- Revenue This Year
- AZTA N/A
- DVAX $21.18
- Revenue Next Year
- AZTA $4.88
- DVAX $16.83
- P/E Ratio
- AZTA N/A
- DVAX N/A
- Revenue Growth
- AZTA 8.56
- DVAX 24.76
- 52 Week Low
- AZTA $23.91
- DVAX $9.22
- 52 Week High
- AZTA $63.58
- DVAX $14.63
- Technical
- Relative Strength Index (RSI)
- AZTA 62.82
- DVAX 66.09
- Support Level
- AZTA $31.27
- DVAX $10.38
- Resistance Level
- AZTA $35.33
- DVAX $11.48
- Average True Range (ATR)
- AZTA 1.60
- DVAX 0.30
- MACD
- AZTA 0.08
- DVAX 0.08
- Stochastic Oscillator
- AZTA 79.87
- DVAX 90.40
About AZTA Azenta Inc.
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has three reportable segments that are Sample Management Solutions, Multiomics, and B Medical Systems. It generates a substantial part of its revenue from its Sample Management Solutions segment.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.